drugset / Trial / NCT02420015

Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia

NCT02420015

Phase 4 Completed 35 enrolled Duke University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to evaluate if a treatment the investigators call iCOMMIT is effective at helping smokers with schizophrenia stop smoking. iCOMMIT is a smoking cessation treatment that combines mobile technology with behavioral strategies, counseling, and medications.

Timeline

Start
2017-03-27
Primary completion
2019-01-24
Completion
2019-01-24

Drugs

EvaluationDrugModalityDoseRoute
Background Bupropion Small molecule 300 mg
Background Nicotine Unknown Topical

Indications